Ventus Therapeutics: Funding, Investors & Team (Oct 2026)
Ventus Therapeutics is a biopharmaceutical company discovering and developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer. Ventus' structural immunology platform offers unprecedented insight into mechanisms and molecular structures, combining core capabilities for precisely targeting the innate immune system: proprietary protein engineering capabilities that elucidate innate immune mechanisms, and leading-edge rational and structure-based drug design tools. Ventus has built an emerging pipeline of multiple drug programs addressing key targets in the innate immune system.
Ventus Therapeutics has raised $240M across 2 funding rounds on record, the most recent a Series C of $140M announced in Feb 2022.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Ventus Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2022.
Ventus Therapeutics Funding Rounds
Ventus Therapeutics raised $100M in a Series B announced in Apr 2021.
10 months later, a Series C of $140M was announced in Feb 2022.
Ventus Therapeutics Founders and Leadership Team
Contact details for the Ventus Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Ventus Therapeutics Funding Compared to Other Biotechnology Startups
Ventus Therapeutics' latest round of $140M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Ventus Therapeutics in Biotechnology and Waltham
Companies Similar to Ventus Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Ventus Therapeutics Funding FAQs
What does Ventus Therapeutics do?
Ventus Therapeutics is a biopharmaceutical company discovering and developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer. Ventus' structural immunology platform offers unprecedented insight into mechanisms and molecular structures, combining core capabilities for precisely targeting the innate immune system: proprietary protein engineering capabilities that elucidate innate immune mechanisms, and leading-edge rational and structure-based drug design tools. Ventus has built an emerging pipeline of multiple drug programs addressing key targets in the innate immune system.
How much funding has Ventus Therapeutics raised?
Ventus Therapeutics has raised $240M across 2 rounds on record. The most recent is a Series C of $140M announced in Feb 2022.
When did Ventus Therapeutics last raise funding?
Ventus Therapeutics' most recent funding round on record is a Series C of $140M, announced in Feb 2022.
Who is the CEO of Ventus Therapeutics?
Marcelo Bigal is listed as CEO at Ventus Therapeutics.
Where is Ventus Therapeutics headquartered?
Ventus Therapeutics is based in Waltham, Massachusetts, United States.
How many employees does Ventus Therapeutics have?
Ventus Therapeutics is in the 51-100 employee band.
How does Ventus Therapeutics' funding compare to other Biotechnology startups?
Ventus Therapeutics' latest round of $140M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Ventus Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ventus Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.